1227605-60-8

Basic information

• Product Name: 6-bromo-5-fluoropyridine-2-carbaldehyde
• Synonyms: 6-bromo-5-fluoropyridine-2-carbaldehyde
• CAS NO: 1227605-60-8
• Molecular Weight: 203.998
• Mol File: 1227605-60-8.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 6-bromo-5-fluoropyridine-2-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-5-fluoropyridine-2-carbaldehyde(1227605-60-8)
• EPA Substance Registry System: 6-bromo-5-fluoropyridine-2-carbaldehyde(1227605-60-8)

Safety Data

• Hazardous Substances Data: 1227605-60-8(Hazardous Substances Data)

Upstream product

• 1052714-46-1 6-bromo-5-fluoro-pyridine-2-carboxylic acid 
• 1227599-50-9 (6-bromo-5-fluoropyridin-2-yl)methanol 
• 1366406-63-4 (6-bromo-5-fluoropyridin-2-yl)methyl acetate 
• 1366406-62-3 2-bromo-3-fluoro-6-methylpyridine 1-oxide 
• 1365812-70-9 2-bromo-6-(dibromomethyl)-3-fluoropyridine 
• 374633-36-0 2-bromo-3-fluoro-6-methylpyridine 
• 1210419-26-3 methyl 6-bromo-5-fluoropyridine-2-carboxylate 

Relevant articles and documents

BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS

This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy.

FACTOR IXA INHIBITORS

In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

GLYCINE TRANSPORTER INHIBITING SUBSTANCES

The present invention aims to provide novel compounds of formula [I] or pharmaceutically acceptable salts thereof that are based on a glycine uptake inhibiting action and which are useful in the prevention or treatment of such diseases as schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, specific phobia, acute stress disorder, etc.), depression, drug addiction, spasm, tremor, pain, and sleep disorder: